January 22, 2020
Making the Value Proposition for Rare Disease Therapies
Read More
January 3, 2020
NICE Rejects Akcea’s FCS Drug Waylivra as Too Costly
Read More
December 11, 2019
The Other Data Drug Developers Need to Consider
Read More
December 6, 2019
Why Payers Lag Drug Developers and Regulators in Embracing Real-World Evidence
Read More
October 9, 2019
When Did Super Become a Bad Thing?
Read More
September 13, 2019
Vertex Reaches Access Agreement with Scottish Government for CF Drugs
Read More
September 4, 2019
NICE Recommends Use of Gene Therapy for Rare Inherited Eye Disorder
Read More
August 19, 2019
ICER’s Final Report on Value of DMD Treatments Leaves Patients Unsatisfied
Read More
August 2, 2019
It’s a Low-Down Dirty Shame
Read More
July 25, 2019
Bipartisan Legislation Seeks to Save Government $100 Billion in Drug Costs
Read More
June 14, 2019
Bluebird Bio Prices TDT Gene Therapy at $1.8 Million
Read More
Load More
X